Klotho Neurosciences (NASDAQ:KLTO) Trading Up 0.6% – What’s Next?

Klotho Neurosciences, Inc. (NASDAQ:KLTO)’s share price was up 0.6% during trading on Thursday . The company traded as high as $0.3950 and last traded at $0.3626. Approximately 667,737 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 779,516 shares. The stock had previously closed at $0.3606.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Klotho Neurosciences in a research note on Monday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Klotho Neurosciences Price Performance

The company has a 50-day moving average price of $0.49 and a two-hundred day moving average price of $0.77. The company has a market cap of $26.30 million, a PE ratio of -1.13 and a beta of 10.05.

Klotho Neurosciences (NASDAQ:KLTO) last announced its earnings results on Thursday, November 13th. The company reported ($0.05) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Klotho Neurosciences stock. Jane Street Group LLC bought a new stake in Klotho Neurosciences, Inc. (NASDAQ:KLTO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned 0.05% of Klotho Neurosciences at the end of the most recent quarter. 20.07% of the stock is currently owned by hedge funds and other institutional investors.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.